Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2003
12/04/2003WO2003025579A3 Use of heart fatty acid binding protein
12/04/2003WO2003024946A3 Oxamate derivatives containing a variously substituted nitrogen heterocycle
12/04/2003WO2003020280A3 Compositions and use thereof in the treatment of cancer
12/04/2003WO2003017991A3 Injection solution containing a dihydropyridin derivative
12/04/2003WO2003017949A3 Novel synthetic ganglioside derivatives and compositions thereof
12/04/2003WO2003015748A3 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
12/04/2003WO2003014145A3 Peptides that bind to atherosclerotic lesions
12/04/2003WO2003006996A3 Natural ligand of gpcr chemr23 and uses thereof
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002078747A8 Pregabalin lactose conjugates
12/04/2003WO2002073208A3 Anti-epileptogenic agents
12/04/2003WO2002070708A3 Glutamate receptor modulatory proteins and nucleic acids encoding them
12/04/2003WO2002065977A3 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
12/04/2003US20030225450 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225272 Novel mmp-2/mmp-9 inhibitors
12/04/2003US20030225271 Compounds useful as reversible inhibitors of cysteine proteases
12/04/2003US20030225270 E.g., 4-acetylamino-N-(1-((4-cyano-1-methylpiperidin-4-yl-carbamoyl)-2 -(cyclohexylethyl)benzamide; Alzheimer's, auto-immune and Crohn's diseases; atherosclerosis; antiarthritic agents; osteoporosis; atherosclerosis
12/04/2003US20030225164 Carbocyclic amines such as 4-(3-(4-Phenylcyclohexylamino)-propyl)phenol, administered as N-Methyl-D-Aspartate (NMDA) receptor inhibitors, for prophylaxis of cardiovascular, brain or nervous system disorders
12/04/2003US20030225160 Esterified hydroxytyrosol; 2-(3,4-dihydroxyphenyl)ethyl acetate for example
12/04/2003US20030225158 Compounds that modulate PPAR activity and methods for their preparation
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225144 Anticoagulants, methyl (2R,3R)-2-(3-(amino(imino)methyl)benzyl)-3-((4-(1-oxido-4-pyridinyl) benzoyl)amino)butanoate; therapeutic treatment of cardiovascular disorders
12/04/2003US20030225141 Thiazole derivatives
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225134 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance
12/04/2003US20030225130 Triphenylalkene derivatives and their use as selective estrogen receptor modulators
12/04/2003US20030225128 For treating conditions such as erectile dysfunction, cardiovascular disorders, male or female sexual dysfunction, diabetes mellitus, and gastrointestinal disorders
12/04/2003US20030225120 Dihydropyridine soft drugs, and related compositions and methods
12/04/2003US20030225116 Substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridine
12/04/2003US20030225115 Anticoagulants
12/04/2003US20030225111 Use of a quinazoline derivative such as 1-(2,6-dichloro-phenyl)-3-(7-(3-morpholinopropoxy)quinazolin-4-yl) urea to produce an antiangiogenic and/or vascular permeability reducing effect
12/04/2003US20030225106 Prophylaxis and treatment of angiogenesis mediated diseases such as cancer
12/04/2003US20030225105 New linear cyclic ureas
12/04/2003US20030225102 Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate
12/04/2003US20030225100 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same
12/04/2003US20030225099 E.g., 1-(phenylethyl)-(2-(6-(2-pyridin-2-ylethylcarbamoyl)-pyridin-2 -yl)benzyl)carbamate; use as antiarrhythmic active compounds
12/04/2003US20030225097 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor
12/04/2003US20030225094 E.g, 4-(2-((6R,12aR)-6-benzo(1,3)dioxol-5-yl-1,4-dioxo -3,4,6,7,12,12a-hexahydro-1H-pyrazino-(1',2':1,6)pyrido(3,4-b) indol-2-yl)ethyl)-benzenesulfonamide; inhibitors of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase
12/04/2003US20030225093 Cyclic gmp-specific phosphodiesterase inhibitors
12/04/2003US20030225092 E.g., 6-Benzo(1,3)dioxol-5-yl-10-hydroxy-2-methyl-2,3,6,7,12, 12a-hexa-hydropyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase
12/04/2003US20030225090 Oxindole derivatives
12/04/2003US20030225089 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
12/04/2003US20030225086 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
12/04/2003US20030225085 For reducing neuronal cell death in response to a traumatic event
12/04/2003US20030225084 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others.
12/04/2003US20030225083 Oxazole derivatives, such as 3-(4-(2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy)-2-(pyridin-2-ylmethoxy) -phenyl)-propionic acid
12/04/2003US20030225080 Treating a disorder responsive to the blockade of sodium channels
12/04/2003US20030225077 Naphthylamines used to chronic inflammatory diseases.
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225072 Opioid receptor active compounds
12/04/2003US20030225070 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
12/04/2003US20030225065 Use of 4-(1,4-diazepan-1-yl)- or 4-piperazin-1-yl-2-aminophenyl phenyl sulfones for treatment of disorders of the central nervous system.
12/04/2003US20030225060 Acylated piperidine derivatives as melanocortin-4 receptor agonists
12/04/2003US20030225057 3-Benzoazepine derivatives
12/04/2003US20030225056 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030225038 Adenosine receptor antagonists and methods of making and using the same
12/04/2003US20030225035 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
12/04/2003US20030225032 Pharmaceutical composition
12/04/2003US20030225020 Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
12/04/2003US20030224987 Binding to formyl peptide receptor or formyl peptide receptor-like 1
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224402 Progression suppressed gene 13 (PSGen 13) and uses thereof
12/04/2003US20030224348 Methods of screening for SCAP antagonists
12/04/2003US20030224347 Pharmaceutical compositions
12/04/2003US20030224343 Kappa-PVIIA-related conotoxins as organ protectants
12/04/2003US20030223991 Modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
12/04/2003US20030223976 Control sequences of the human corin gene
12/04/2003US20030223969 Method of modulating inflammatory response
12/04/2003CA2784937A1 Ccr9 inhibitors and methods of use thereof
12/04/2003CA2489145A1 Insulin-sensitizing agent
12/04/2003CA2487732A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487441A1 Novel uses of parapoxvirus preparations
12/04/2003CA2487303A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003CA2487273A1 Agents and methods for the treatment of disorders associated with oxidative stress
12/04/2003CA2487269A1 Novel exendin agonist formulations and methods of administration thereof
12/04/2003CA2487167A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003CA2487153A1 New formulation for the parenteral application of crobenetine
12/04/2003CA2487150A1 New formulation for parental application of sodium channel blocker
12/04/2003CA2487143A1 Regulation of novel human asparagine-hydroxylases
12/04/2003CA2487112A1 Neuregulin based methods and compositions for treating cardiovascular diseases
12/04/2003CA2487073A1 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003CA2486966A1 Substituted quinazolinone compounds
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2486821A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486651A1 Sulfone liver x-receptor modulators
12/04/2003CA2486644A1 Anilino liver x-receptor modulators
12/04/2003CA2486564A1 Acetamides and benzamides that are useful in treating sexual dysfunction
12/04/2003CA2486376A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
12/04/2003CA2485984A1 Pharmaceutical combination of pde5 inhibitors with ace inhibitors
12/04/2003CA2485184A1 Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
12/04/2003CA2485166A1 Substituted pyrimidinone and pyridinone compounds
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484656A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003CA2484288A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
1 ... 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 ... 1595